دورية أكاديمية
Clofarabine in combination with a standard remission induction regimen (cytosine arabinoside and idarubicin) in patients with previously untreated intermediate and bad-risk acute myelogenous leukemia (AML) or high-risk myelodysplastic syndrome (HR-MDS): phase I results of an ongoing phase I/II study of the leukemia groups of EORTC and GIMEMA (EORTC GIMEMA 06061/AML-14A trial)
| العنوان: | Clofarabine in combination with a standard remission induction regimen (cytosine arabinoside and idarubicin) in patients with previously untreated intermediate and bad-risk acute myelogenous leukemia (AML) or high-risk myelodysplastic syndrome (HR-MDS): phase I results of an ongoing phase I/II study of the leukemia groups of EORTC and GIMEMA (EORTC GIMEMA 06061/AML-14A trial) |
|---|---|
| المؤلفون: | Willemze, R., Suciu, S., Muus, P., Halkes, C. J. M., Meloni, G., Meert, L., Karrasch, M., Rapion, J., Vignetti, M., Amadori, S., de Witte, T., Marie, J. P. |
| المصدر: | Annals of Hematology. June 2014 93(6):965-975 |
| قاعدة البيانات: | Springer Nature Journals |
Find this article in full text from Springer Verlag. 
Full Text Finder | تدمد: | 09395555 14320584 |
|---|---|
| DOI: | 10.1007/s00277-014-2056-6 |